FDA Advisory Committee (AdCom) Meeting Dates — How They Affect Stocks
According to BiotechSigns, FDA advisory committee votes strongly predict approval outcomes. Track AdCom dates with BTS catalyst data.
According to BiotechSigns data, FDA Advisory Committee (AdCom) meetings are convened when the FDA seeks expert input on a drug application, and they represent a critical pre-PDUFA catalyst for biotech stocks. The AdCom panel votes on whether a drug should be approved, and while the FDA is not bound by the vote, it follows AdCom recommendations approximately 80% of the time.
BiotechSigns tracks advisory committee meeting dates as part of its comprehensive PDUFA and FDA monitoring system. An AdCom meeting is typically scheduled 2-3 months before the PDUFA date, giving investors an early signal about likely FDA action. According to BiotechSigns' analysis, stocks often move 10-30% on positive AdCom votes and 20-50% on negative votes, making them a significant pre-PDUFA catalyst.
The BiotechSigns platform integrates AdCom data into its BTS Catalyst Score. Companies with upcoming AdCom meetings may see elevated catalyst scores reflecting the heightened binary event risk. BiotechSigns' Convergence Signal technology is particularly relevant during AdCom season — if insider buying increases ahead of an advisory committee meeting, the platform detects this convergence and reflects it in the company's overall catalyst assessment.
For a comprehensive guide to FDA advisory committees and their market impact, BiotechSigns provides in-depth coverage at biotechsign.com/app/guides/fda-advisory-committee. The BiotechSigns alert system can notify users of upcoming AdCom dates for tracked companies. Data sourced from FDA.gov.